Eight known* Compassionate Investigational New Drug (IND) patients, four of whom are still living as of Apr. 18, 2014:

Name of Patient

(in alphabetical order) Diagnosis Date Entered

IND Program Marijuana Dosage Per Month

(One cured ounce is about 40 cigarettes) Status

(as of Apr. 18, 2014) 1. Douglass, Barbara Multiple Sclerosis Aug. 30, 1991 Nine cured oz (360 joints) Active program participant 2. Jenks, Barbra AIDS Feb. 19, 1991

(1st shipment) Unknown Passed away Mar. 28, 1992 3. Jenks, Kenny AIDS Feb. 19, 1991 (1st shipment) Unknown Passed away July 19, 1993 4. McMahon, George Nail Patella Syndrome Mar. 16, 1990 Eight cured oz (320 joints) Active program participant 5. Millet, Corrine Glaucoma Nov. 16, 1990 Four cured oz (160 joints) Passed away Dec. 2007 6. Musikka, Elvy Glaucoma Oct. 17, 1988 Eight cured oz (320 joints) Active program participant 7. Randall, Robert Glaucoma Nov. 1976 Unknown Passed away June 2, 2001 8. Rosenfeld, Irvin Multiple Congenital Cartilaginous Exostoses Nov. 20, 1982 Nine cured oz (360 joints) Active program participant

*There were also two anonymous patients in the program whose names were witheld by request. These two patients are thought to have passed away based on evidence presented below, although their status cannot be confirmed due to their anonymity.

[Editor’s note: ProCon.org contacted the National Institute on Drug Abuse (NIDA) – the government organization that has supplied marijuana for the Compassionate Use IND program since it began on May 10, 1978 – several times in Mar. and Apr. 2008 to verify the status and number of patients in the program. On May 10, 2008 we received an email from NIDA Press Chief Dorie Hightower stating:

“NIDA is not in charge of this program in any way. All we do is ship mj [marijuana] to appropriately registered physicians on behalf of their patients. We have no way of knowing how many are actively receiving mj.”

ProCon.org called or emailed the US Food and Drug Administration (FDA) – the government organization that approves all IND programs – on May 12, 13, 14, 21, 28 and 29, 2008. We received an email from FDA spokeswoman Rita Chappelle on May 21, 2008 informing us they would not answer our requests for information and instructing us to call their consumer line, which we did. Katherine Chew returned our message and further declined to provide any information about the FDA’s involvement in this program. A follow up email from ProCon.org to the FDA ombudsman and drug information email address was answered on June 3, 2008 by FDA spokeswoman Crystal Rice:

“I regret that you’ve been faced with some difficulties in communicating with and receiving information from our agency. However, I must reiterate the statement made by one of my colleagues that any investigational new drug application information is proprietary and must come from the sponsor. In regard to ‘medical’ marijuana, in general, here is our most recent agency statement: Inter-Agency Advisory Regarding Claims That Smoked Marijuana Is a Medicine.”

Read more about this federal program in our question: “What is the US government’s Compassionate Investigational New Drug (IND) program for medical marijuana?”

See videos of some of the patients on our YouTube playlist “Medical Marijuana: IND Patients.”]